Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma (ATA129-NPC-202)

Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Neoplasms;   Epstein-Barr Virus Infections;   Epstein-Barr Viraemia
Interventions:   Biological: tabelecleucel;   Biological: pembrolizumab
Sponsors:   Atara Biotherapeutics;   Merck Sharp & Dohme Corp.
Recruiting

https://ift.tt/2Upqr3p